We are excited to announce the publication of a new article in Biopharma Dealmakers, a magazine by Springer Nature, featuring our innovative approach to achieving a functional cure for HIV.
The article provides an in-depth assessment of our scientific strategy, the underlying technology platform, and the potential to fundamentally change the treatment landscape for people living with HIV.
Our goal is to enable long-term viral control without the need for lifelong antiretroviral therapy. The article outlines our progress in R&D and our development pipeline.
👉 Read the full article here: Precise genome-editing technology to cure HIV
We thank Biopharma Dealmakers for the opportunity to share our work with a global audience and look forward to continued collaboration with partners across science and industry.